GET DAILY SIGNALSInsmed (INSM) Delivers Strong +268% Revenue Growth in Q3 2026
Key Takeaways
- Insmed reported third-quarter 2026 total revenue of $524.4 million, up 268% year over year and above the roughly $501 million consensus estimate.
- BRINSUPRI (brensocatib) delivered $400.1 million in quarterly revenue, up 29% sequentially and crossing the $1 billion blockbuster threshold in its first four full quarters of launch.
- ARIKAYCE (amikacin liposome inhalation suspension) generated $124.4 million, up 9% year over year, driven by international growth.
- Net loss was $100.3 million, or $0.46 per share, wider than the consensus loss estimate but a sharp improvement from the $1.75 per-share loss a year earlier.
- Management raised full-year 2026 revenue guidance for both products, and the company launched BRINSUPRI Tablets in Japan during the quarter.
Why the Earnings Matter
Insmed’s third-quarter 2026 report provides a useful checkpoint on whether the company’s lead product can turn rapid top-line growth into a clearer route to profitability. BRINSUPRI has quickly become the primary growth driver for the treatment of bronchiectasis, while ARIKAYCE continues to deliver more measured but reliable contributions. I’m watching closely to see how operating expenses, R&D outlays, and gross margins develop as the commercial portfolio expands. With shares trading well below their 52-week high ahead of the release, the report served as an important test of management’s ability to demonstrate sustainable long-term value amid ongoing net losses.
Quarterly Results in Detail
For the three months ended September 30, 2026, INSM posted total revenue of $524.4 million, a 268% increase from $142.3 million in the same period a year earlier. The result topped the consensus estimate of roughly $501 million. BRINSUPRI accounted for $400.1 million of the total, while ARIKAYCE contributed $124.4 million.
The company recorded a net loss of $100.3 million, or $0.46 per share, compared with a net loss of $370.0 million, or $1.75 per share, in the prior-year quarter. The per-share loss exceeded consensus expectations, reflecting higher operating costs. R&D expenses rose to $270.0 million from $186.4 million, and selling, general, and administrative expenses increased to $253.0 million from $186.4 million. Even so, the operating loss narrowed meaningfully to $89.4 million from $366.0 million a year earlier.
Management lifted full-year 2026 guidance for both products. BRINSUPRI revenue is now expected in the range of $1.35 billion to $1.4 billion, while ARIKAYCE guidance was raised to $460 million to $470 million. Cash, cash equivalents, and marketable securities stood at approximately $1.1 billion at the end of the quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Sentiment
Shares of INSM climbed roughly 13% after the release, buoyed by the revenue beat and the raised full-year outlook. Investors focused on BRINSUPRI’s ongoing commercial momentum and the launch in Japan, which management described as a meaningful growth opportunity not yet factored into 2026 guidance. Some analysts noted that the wider-than-expected per-share loss and elevated spending warrant attention, and sequential growth in BRINSUPRI moderated compared with the earliest quarters of the launch. Overall, the positive revenue and guidance revisions appear to have outweighed near-term profitability concerns.
Looking Ahead
Going forward, the key question is whether INSM can maintain BRINSUPRI’s growth pace while moderating the pace of spending. Management noted that additional investment in clinical programs and Japan commercial infrastructure in the fourth quarter will pressure near-term cash burn, even as the company aims for cash-flow positivity in 2027.
Regulatory and pipeline events represent further potential catalysts. The FDA has accepted a supplemental New Drug Application for ARIKAYCE in MAC lung disease, with possible label-expansion launches in the U.S. and Japan expected in the first half of 2027 if approved. The company is also advancing its Phase 3 TPIP program across several sizable indications.
Items to monitor include the speed of BRINSUPRI uptake in Japan, gross-to-net trends for both products, expense discipline, and progress toward cash-flow positivity. Management has outlined long-term peak sales potential exceeding $7 billion for BRINSUPRI and $6 billion for TPIP, though those figures hinge on successful clinical and commercial execution.
My Take on Tickeron’s AI Tools
From what I see in my own workflow, Tickeron’s AI Screener helps me quickly filter stocks by technical patterns, fundamentals, and AI-driven signals so I can compare INSM against peers without spending hours on manual screens. It supports a more systematic approach when I’m building or refining a watchlist around earnings or sector moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INSM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for INSM turned positive on October 27, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in 39 of 52 cases over the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on INSM as a result. In 71 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +16.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 202 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
INSM moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INSM crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
INSM broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INSM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.456) is normal, around the industry mean (3.154). P/E Ratio (-27.325) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement